Opiranserin (VVZ-149) is a novel non-opioid, non-steroidal intravenous analgesic with triple antagonistic activity at glycine transporter 2 (GlyT2), purine 2 receptor 3 (P2X3), and serotonin receptor (5-HT2A). Its half-maximal inhibitory …
Endometriosis is a debilitating, estrogen-dependent gynecological disorder characterized by profound diagnostic delays due to clinical reliance on invasive laparoscopy. Developing noninvasive, point-of-care biomarker assessment remains a critical yet unmet medical …
This study aimed to evaluate the impact of an 8 weeks functional strength training program on physical performance, pain perception, and quality of life in women with endometriosis.
This study explored the genetic evidence linking triglyceride-related pathways and lipid-lowering drug targets with endometriosis risk and investigated the genetic association between TG levels and EM. Using genome-wide association study …
Melatonin has evolved from its classical role as a pineal-derived circadian regulator to a molecule increasingly recognized for its mitochondrial and cytoprotective functions. This review examines the molecular mechanisms and …
Rheumatic heart disease (RHD) remains the leading cause of acquired valvular heart disease in low- and middle-income countries, affecting an estimated 40 million individuals and disproportionately affecting children and young …
The anion exchanger 1 (AE1), traditionally known for its role in erythrocyte anion transport and acid-base homeostasis, has recently been identified in non-erythroid tissues, suggesting broader physiological functions. In the …
The research by Chen et al. (2024) presents an innovative hypothesis linking creatine metabolism to ferroptosis resistance in endometriotic stromal cells via PrP suppression. While conceptually valuable, methodological aspects warrant …
This study aimed to compare the clinical histories and clinicopathological characteristics between internal and external adenomyosis (ADM) among infertile women. A total of 759 infertile patients aged 24 to 40 …